IPLEX health benefits

IPLEX
Potential health benefits and research finds 2007

Insmed Inc.'s IPLEX(TM) (rhIGFI/rhIGFBP-3) will be
available to physicians in Italy to treat patients with
Amyotrophic Lateral Sclerosis (ALS) soon. IGF-1 is a
neurotrophic factor essential for normal growth of the
nervous system. In animals and cell culture systems
IGF-1 protects motor neurons and promotes muscle and
nerve regeneration. Through an agreement with
Cephalon, which holds European patent rights to IGF-1
pertaining to the treatment of ALS, Insmed will be able to
provide IPLEX to physicians in Italy.

IPLEX (rhIGF-I/rhIGFBP-3) is a complex of recombinant
human insulin-like growth factor-I (rhIGF-I) and its
predominant binding protein IGFBP-3 (rhIGFBP-3), It was
approved by FDA in the summer of 2006 to treat children
with short stature associated with severe primary IGF-I
deficiency (Primary IGFD). Currently, the drug is being
investigated for various other indications including severe
insulin resistance, myotonic muscular dystrophy and
HIV-Associated Adipose Redistribution Syndrome (HARS).

Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou
Gehrig's Disease) Press Release Wednesday January 10, 9:00 am ET

Motor neurons reach from the brain to the spinal cord and from the spinal cord to the
muscles throughout the body. Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's
Disease, is a neurodegenerative disorder that causes progressive muscle weakness and
loss of motor neurons. When the motor neurons die, patients may become totally
paralyzed. There are an estimated 1000 new cases of ALS per year in Italy.